← Back

Wire · regulatory

Tandem Mobi sees FDA clearance for tubeless AID system

Published

16 November 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 16 November 2026 · Fusion42 review

Tandem Mobi has received FDA clearance for its tubeless Automated Insulin Delivery (AID) system, marking a significant regulatory milestone in diabetes management technology in the United States.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 13 Nov 2026 and 16 Nov 2026.

◆ ◆ The Wire takeaway

The FDA clearance opens a direct sales path for you in US diabetes treatment tech and sets a benchmark your rivals will chase. Expect faster adoption but also more competition from this point.

◆ Coverage

2 sources · first reported 13 Nov 2026 · latest 16 Nov 2026

◆ Related on Wire

◆ Topics

Medtechfda-clearancediabetes-techmedtechautomation